The biopharmaceutical industry is uniquely prepared to combat COVID-19.
Of the 53,109 ADR reports received in 2012, almost 80 per cent were categorized as “serious.”
In a recent speech, federal Health Minister Jane Philpott acknowledged that Canada’s health-care system is in desperate need of repair.
The recent announcement of an agreement in principle on the free trade deal between Canada and the European Union is no doubt a positive development for the Canadian economy and ultimately Canadian incomes and standards of living. Part of the agreement getting some misinformed attention however pertains to improvements in Canadian protections of pharmaceutical innovator intellectual property.